DDInter1628 DDInter979
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma.[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.
Ruxolitinib {u} (Compound) downregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) POLR1C
POLR1C {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) downregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) binds {v} (Gene) CLK2
CLK2 {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DYRK1A
DYRK1A {u} (Gene) is downregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Isatuximab
Ruxolitinib (Compound) downregulates BLCAP (Gene) and BLCAP (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) upregulates POLR1C (Gene) and POLR1C (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) downregulates BLCAP (Gene) and BLCAP (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) upregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) downregulates DNAJB2 (Gene) and DNAJB2 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Isatuximab
Ruxolitinib (Compound) binds CLK2 (Gene) and CLK2 (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) binds DYRK1A (Gene) and Ruxolitinib (Compound) upregulates DYRK1A (Gene) and DYRK1A (Gene) is downregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoposide (Compound) and PTGS2 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Isatuximab